San Francisco) CK-2127107 Molecule activator of the fast skeletal muscle troponin complex Conditions associated with neuromuscular dysfunction, muscular weakness and/or muscle fatigue Started a Phase I trial 4/2/13 Immunomic Therapeutics Inc. (Lancaster, Pa.) JRC-LAMP-vax Immunothera-peutic vaccine Red cedar allergy Phase I data showed it met all of its primary safety endpoints 4/25/13 Lipocine Inc. (Salt Lake City) LPCN 1111 Next-generation oral testosterone replacement product Testosterone
Company (Location) Product Description Indication Status Date AUTOIMMUNE Rigel Pharmaceuticals Inc. (South San Francisco) and AstraZeneca plc (London) Fostamatinib Oral spleen tyrosine kinase inhibitor Rheumatoid arthritis Missed the X-ray endpoint of modified Total Sharp score, but hit statistical significance in ACR20 scoring, although the Phase III still fell short of those achieved by Pfizer Inc.'s approved Xeljanz 4/8/13 CANCER Array BioPharma Inc. (Boulder, Colo.) ARRY-520 A selective KSP
once-daily Multiple sclerosis Was approved in Argentina in a 14 mg formulation for patients with relapsing forms 4/9/13 CANCER Celgene Corp. (Summit, N.J.) Revlimid Lenalidomide Transfusion-dependent anemia CHMP adopted a positive opinion for Revlimid 4/29/13 Curis Inc. (Lexington, Mass.) Erivedge Vismodegib Symptomatic metastatic basal cell carcinoma CHMP recommended conditional approval 4/29/13 Medivation Inc. (San Francisco) and Astellas Pharma Inc. (Tokyo) Xtandi Enzalutamide Metastatic
San Francisco) and GlaxoSmithKline plc (London) Breo Fluticasone furoate (FF)/vilanterol (VI), the combination corticosteroid and long-acting beta2 agonist Chronic obstructive pulmonary disease FDA committee recommended approval 4/18/13 Tris Pharma Inc. (Monmouth Junction, N.J.) Karbinal ER Carbinoxamine maleate extended-release oral suspension Seasonal and perennial allergic rhinitis FDA approved it 4/4/13 MISCELLANEOUS Enlivex Therapeutics Ltd. (Jerusalem) ApoCell A treatment based on inducing
Jennerex Biotherapeutics Inc., of San Francisco, said the FDA granted orphan drug status for Pexa-Vec (JX-594, pexastimogene devacirepvec) for the treatment of hepatocellular carcinoma (HCC
Exelixis Inc. , of South San Francisco, reported net revenues for the quarter ended March 31, 2013, were $9.7 million, compared to $18.5 million for the comparable period in 2012...Onyx Pharmaceuticals Inc. , of South San Francisco, reported a doubling of its total revenues to $145.5 million in its financial results for the first quarter 2013, as compared to total revenue of $72 million for the comparable period in 2012
Portola Pharmaceuticals Inc., of South San Francisco, Calif., reported safety and efficacy data from a Phase II proof-of-concept study of PRT4445 of Eliquis (apixaban) in healthy volunteers
SAN FRANCISCO – When AiCuris GmbH, of Wuppertal, Germany, analyzed the market for human cytomegalovirus (HCMV) therapies, it found a market with high medical need, neglected by big pharma, featuring a variety of disease manifestations...Rubsamen-Schaeff accepted the award on behalf of AiCuris at an award banquet recently at the Palace Hotel in San Francisco
By Catherine Shaffer | BioWorld International | Wednesday, May 8, 2013
VistaGen Therapeutics Inc., of South San Francisco, said its human pluripotent stem cell-derived cardiomyocytes were used by collaboration partner Duke University to grow three-dimensional (3D) human heart muscle
Portola Pharmaceuticals Inc., of South San Francisco, set the price range for its proposed initial public offering (IPO), aiming to sell 6.9 million shares priced between $13 and $16 each
By Catherine Shaffer | BioWorld Today | Wednesday, May 8, 2013
LLC acted as exclusive placement agent 4/19/13 Ohr Pharmaceutical Inc. (New York) Exercise of Series B warrants N/A $5.05 Ohr raised about $5.05M from institutional and accredited shareholders through the exercise of Series B warrants 4/23/13 OxiGene Inc. (South San Francisco) Private placement of zero coupon convertible preferred stock Convertible into 1.38S $5 OxiGene raised $5M through the placement...StemCells issued SVB a warrant to purchase 293,531 shares of common stock at $1.7034 per share
Early Bird Gene Mutation Linked to Migraine A group of scientists from the University of California at Los Angeles and the University of California at San Francisco discovered a gene mutation that is linked to both familial advanced phase sleep syndrome, in which individuals go to bed and wake up very early, and migraine
San Francisco $10 Cleave raised $10M in an extension of its Series A round from New Enterprise Associates, bringing its Series A total to $54M 4/10/13 Cydan LLC Cambridge, Mass. $16 Cydan received $16M from investors led by New Enterprise Associates and Pfizer Venture Investments
A report from real estate firm Jones Lang LaSalle in March lists San Diego as the number two biotechnology cluster in the U.S. Like any list, the ranking is debatable, especially by people in the San Francisco Bay Area who came in third
By Brian Orelli | BioWorld Insight | Monday, May 6, 2013
Hyperion Therapeutics Inc., of South San Francisco, said the FDA notified the firm that Ravicti (glycerol phenylbutyrate) qualified for orphan drug exclusivity, giving the product exclusivity on the market for seven years from the date of approval on Feb. 1
Kadcyla is marketed by Roche AG unit Genentech Inc., of South San Francisco